Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2000;(2):CD001043.
doi: 10.1002/14651858.CD001043.

Beta-sitosterols for Benign Prostatic Hyperplasia

Affiliations
Review

Beta-sitosterols for Benign Prostatic Hyperplasia

T Wilt et al. Cochrane Database Syst Rev. .

Abstract

Objectives: This systematic review aimed to assess the effects of beta-sitosterols (B-sitosterol) on urinary symptoms and flow measures in men with of benign prostatic hyperplasia (BPH).

Search strategy: Trials were searched in computerized general and specialized databases (MEDLINE, EMBASE, Cochrane Library, Phytodok), by checking bibliographies, and by contacting manufacturers and researchers.

Selection criteria: Trials were eligible for inclusion provided they (1) randomized men with BPH to receive B-sitosterol preparations in comparison to placebo or other BPH medications, and (2) included clinical outcomes such as urologic symptom scales, symptoms, or urodynamic measurements.

Data collection and analysis: Information on patients, interventions, and outcomes was extracted by at least two independent reviewers using a standard form. Main outcome measure for comparing the effectiveness of B-sitosterols with placebo and standard BPH medications was the change in urologic symptom scale scores. Secondary outcomes included changes in nocturia as well as urodynamic measures (peak and mean urine flow, residual volume, prostate size). Main outcome measure for side effects was the number of men reporting side effects.

Main results: 519 men from 4 randomized, placebo-controlled, double-blind trials, (lasting 4 to 26 weeks) were assessed. 3 trials used non-glucosidic B-sitosterols and one utilized a preparation that contained 100% B-sitosteryl-B-D-glucoside. B-Sitosterols improved urinary symptom scores and flow measures. The weighted mean difference (WMD) for the IPSS was -4.9 IPSS points (95%CI = -6.3 to -3.5, n = 2 studies). The WMD for peak urine flow was 3.91 ml/sec (95%CI = 0.91 to 6.90, n = 4 studies) and the WMD for residual volume was -28.62 ml (95%CI = -41. 42 to -15.83, n = 4 studies). The trial using 100% B-sitosteryl-B-D-glucoside (WA184) show improvement in urinary flow measures. B-sitosterols did not reduce prostate size. Withdrawal rates for men assigned to B-sitosterol and placebo were 7.8% and 8. 0%, respectively.

Reviewer's conclusions: The evidence suggests non-glucosidic B-sitosterols improve urinary symptoms and flow measures. Their long term effectiveness, safety and ability to prevent BPH complications are not known.

Similar articles

  • Serenoa repens for benign prostatic hyperplasia.
    Wilt T, Ishani A, Mac Donald R. Wilt T, et al. Cochrane Database Syst Rev. 2002;(3):CD001423. doi: 10.1002/14651858.CD001423. Cochrane Database Syst Rev. 2002. PMID: 12137626 Updated. Review.
  • Serenoa repens for benign prostatic hyperplasia.
    Wilt T, Ishani A, Stark G, MacDonald R, Mulrow C, Lau J. Wilt T, et al. Cochrane Database Syst Rev. 2000;(2):CD001423. doi: 10.1002/14651858.CD001423. Cochrane Database Syst Rev. 2000. PMID: 10796790 Updated. Review.
  • Cernilton for benign prostatic hyperplasia.
    Wilt T, Mac Donald R, Ishani A, Rutks I, Stark G. Wilt T, et al. Cochrane Database Syst Rev. 2000;(2):CD001042. doi: 10.1002/14651858.CD001042. Cochrane Database Syst Rev. 2000. PMID: 10796739 Updated. Review.
  • WITHDRAWN: Cernilton for benign prostatic hyperplasia.
    Wilt TJ, Macdonald R, Ishani A, Rutks I, Stark G. Wilt TJ, et al. Cochrane Database Syst Rev. 2011 May 11;(5):CD001042. doi: 10.1002/14651858.CD001042.pub2. Cochrane Database Syst Rev. 2011. PMID: 21563128 Review.
  • Pygeum africanum for benign prostatic hyperplasia.
    Wilt T, Ishani A, Mac Donald R, Rutks I, Stark G. Wilt T, et al. Cochrane Database Syst Rev. 2002;1998(1):CD001044. doi: 10.1002/14651858.CD001044. Cochrane Database Syst Rev. 2002. PMID: 11869585 Free PMC article. Review.
See all similar articles

Cited by 22 articles

See all "Cited by" articles

LinkOut - more resources

Feedback